RxDoctor Payments Data

Gem Martin

Nurse Practitioner · Port St Lucie, FLNPI 1689135329

Payments from drug & device makers

$710in general payments, 2019–2025

Across 28 payments — averaging $25.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$125
  • Esperion Therapeutics, Inc.$111
  • Pfizer$86
  • AstraZeneca$63
  • Pharmacyclics LLC, An Abbvie Company$58
  • Novo Nordisk$45
  • plus $223 from 10 others

What the payments were for

  • Food & beverage$710100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$710 in reported general payments places this provider in the 65th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$27,564
Medicare patients
112
Services billed
274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$55,981
EliquisApixaban31$35,898
JardianceEmpagliflozin28$29,274
SymbicortBudesonide/Formoterol Fumarate30$8,771
Albuterol Sulfate HfaAlbuterol Sulfate144$3,135
Varenicline Tartrate20$2,020
Ventolin HfaAlbuterol Sulfate24$1,773
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,494
Gabapentin103$1,430
Scopolamine11$1,229
Tolterodine Tartrate21$1,106
Omeprazole72$1,088
Diclofenac Sodium31$893
Atorvastatin Calcium112$820
Trazodone Hcl63$699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$14$55,98154 claims
PfizerEliquis$86$35,89831 claims
Boehringer IngelheimJardiance$125$29,27428 claims
AstraZenecaSymbicort$63$8,77130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Port St Lucie

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →